A systematic review of restaging after induction therapy for stage IIIa lung cancer: Prediction of pathologic stage

Journal of Thoracic Oncology

Volumn 5, Issue 3, 2010, Pages 389-398

  De Cabanyes Candela, Sara ^a   Detterbeck, Frank C ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Induction; Lung cancer; Pathologic; Restaging; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ECHOGRAPHY; ESOPHAGUS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REPEAT PROCEDURE; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 77649330465     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ce3e5e     Document Type: Review

References (60)

1. Bülzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992;70:1102-1110.
2. Detterbeck F, Sukumar M. Management algorithms for stage IIIA non-small cell lung cancer with N2 node involvement. In M Sukumar (Ed.), Thoracic Surgery Clinics-Management of N2/IIIA Non-Small Cell Lung Cancer. New York: Elsevier, 2008. Pp. 437-441.
3. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
4. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 2004;15: 389-398.
5. Bueno R, Richards W, Swanson S, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-1831.
6. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450.
7. Detterbeck F, Puchalski J, Rubinowitz A, et al. Classification of the thoroughness of mediastinal staging of lung cancer. Chest. In press.
8. Vecchio TJ. Predictive value of a single diagnostic test in unselected populations. N Engl J Med 1966;274:1171-1173.
9. Detterbeck FC, Jones DR, Parker LA Jr, et al. Intrathoracic staging. In Detterbeck FC, Rivera MP, Socinski MA, et al. (Eds.), Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia: W.B. Saunders, 2001. Pp. 73-93.
10. Detterbeck F, Socinski M, Gralla R, et al. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage nonsmall cell lung cancer. J Thorac Oncol 2008;3:37-45.
11. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (exept T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
12. Pisters KMW, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000;119:429-439.
13. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-1374.
14. Betticher DC, Hsu Schmitz S-F, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759.
15. Margaritora S, Cesario A, Galetta D, et al. Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur J Cardiothorac Surg 2001;19:894-898.
16. Burkes R, Ginsberg R, Shepherd F, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-smallcell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992;10:580-586.
17. Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622-634.
18. Pujol J-L, Hayot M, Rouanet P, et al. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer. Chest 1994;106:1451-1455.
19. Weitberg AB, Yashar J, Glicksman AS, et al. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. Eur J Cancer 1993;29A:511-515.
20. Darwish S, Minotti V, Crinò L, et al. A Phase II trial of combined chemotherapy and surgery in Stage IIIA non-small cell lung cancer. Lung Cancer 1995;12(suppl 1):S71-S78.
21. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992;10:1237-1244.
22. Cerfolio R, Bryant A, Winokur T, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-1909; discussion 1909.
23. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13:3255-3263.
24. Berghmans TD, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and metaanalysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
25. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of cancer and leukemia group B protocol 8935: a multiinstitutional phase II trimodality trial for stage IIIA(N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995;109:473-485.
26. Yashar J, Weitberg AB, Glicksman AS, et al. Preoperative chemotherapy and radiation therapy for stage IIIa carcinoma of the lung. Ann Thorac Surg 1992;53:445-448.
27. Kirn DH, Lynch TJ, Mentzer SJ, et al. Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer: impact of preoperative chemotherapy on resectability and downstaging. J Thorac Cardiovasc Surg 1993;106:696-702.
28. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006;24:3333-3339.
29. Stigt JA, Oostdijk AH, Timmer PR, et al. Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2009;66: 198-204.
30. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-8370.
31. De Waele M, Serra-Mitjans M, Hendriks J, et al. Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. Eur J Cardiothorac Surg 2008;33:824-828.
32. Stamatis G, Fechner S, Hillejan L, et al. Repeat mediastinoscopy as a restaging procedure. Pneumologie 2005;59:862-866.
33. Marra A, Hillejan L, Fechner S, et al. Remediastinoscopy in restaging of lung cancer after induction therapy. J Thorac Cardiovasc Surg 2008; 135:843-849.
34. Detterbeck F. Surgical evaluation of the mediastinum. In Pass H, Carbone D, Johnson DH, et al. (Eds.), Lung Cancer: Principles and Practice, 4th Ed. Philadelphia: Lippincott, Williams & Wilkins, 2009.
35. Jaklitsch MT, Gu L, Harpole DH, et al. Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): results of CALGB 39803. In Proceedings of the ASCO Annual Meeting, 2005; Orlando, FL.
36. Kunst PW, Lee P, Paul MA, et al. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer. J Thorac Oncol 2007;2:912-915.
37. Annema JT, VeseliçM, Versteegh MI, et al. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer 2003;42:311-318.
38. Herth FJF, Annema JT, Eberhardt R, et al. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol 2008;26:3346-3350.
39. Detterbeck F, Jantz M, Wallace M, et al. Invasive mediastinal staging of lung cancer: an ACCP evidence based clinical practice guideline (2nd edition). Chest 2007;132:202S-220S. (Pubitemid 47502808)
40. Schenk DA, Bower JH, Bryan CL, et al. Transbronchial needle aspiration staging of bronchogenic carcinoma. Am Rev Respir Dis 1986;134: 146-148.
41. Wiersema MJ, Vazquez-Sequeiros E, Wiersema LM, et al. Evaluation of mediastinal lymphadenopathy with endoscopic US-guided fine-needle aspiration biopsy. Radiology 2001;219:252-257.
42. Annema JT, Versteegh MI, Veselic M, et al. Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. JAMA 2005;294:931-936.
43. Lardinois D, Schallberger A, Betticher D, et al. Postinduction videomediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. Ann Thorac Surg 2003;75:1102-1106.
44. Zielinski M, Hauer L, Hauer J, et al. Non-small cell lung cancer restaging with the transcervical extended mediastinal lymphadenectomy. Eur J Cardiothorac Surg In press.
45. Faber LP, Kittle CF, Warren WH, et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989;47:669-677.
46. Junker K, Thomas M, Schulmann K, et al. Tumour regression in non-small cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123:469-477. (Pubitemid 27436005)
47. Cerfolio R, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938-944.
48. Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158. (Pubitemid 24026882)
49. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-187.
50. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463-471. (Pubitemid 46426996)
51. Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004; 128:892-899.
52. Choi N, Fischman A, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024-1035.
53. Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemotherapy. Clin Cancer Res 2006;12:97-106.
54. Ohtsuka T, Nomori H, Ebihara A, et al. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2006;12:89-94.
55. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73:259-266.
56. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004;77:254-259.
57. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2000;70:391-395.
58. Cerfolio RJ, Bryant AS, Ojha B, et al. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131:1229-1235.
59. Meersschaut D, Vermassen F, de la Rivière AB, et al. Repeat mediastinoscopy in the assessment of new and recurrent lung neoplasm. Ann Thorac Surg 1992;53:120-122.
60. Varadarajulu S, Eloubeidi MA. Can endoscopic ultrasonography-guided fine-needle aspiration predict response to chemoradiation in non-small cell lung cancer? A pilot study. Respiration 2006;73:213-220.